Beta
280058

Frequency of Metallo-Β-Lactamase Among Pseudomonas aeruginosa Isolated from patients In Intensive Care Units and Operating Rooms

Article

Last updated: 03 Jan 2025

Subjects

-

Tags

-

Abstract

Background: P.aeruginosa infection is one of the major health problems in the world. It's an opportunistic human pathogen that causes serious problems. Usually resistant to several antibiotics, show a particular ability to spread in hospitals. In recent times, Metallo-β-lactamase resistance in this bacterium has imposed some difficulties in treating bacterial infections. This study was a qualitative study, aimed to detect Metallo-β-Lactamase in Carbapenems-resistant P. aeruginosa isolated from inpatients admitted to Intensive Care Unit and Operating Room in different hospitals in Jeddah city, KSA during the period from March 2019 to September 2022.Methods: In this study, a total of (234) were cultured and identified using API 12A/12E. All isolates were subjected to antimicrobial susceptibility testing using Kirby Bauer method, for selected imipenem and meropenem. Results: Out of 234 specimens 154 Pseudomonas aeruginosa were isolated and identified, with different ratios (males, 62.3: females, 37.7), which occurred highest in the adult age group. The highest frequency of isolate 152 (98.7%) was in the intensive care unit while the lowest frequency of isolate 2 (1.3%) was in the operating room. (9%), (5.8%), (10.38%) and (1.2%) were found resistant to imipenem, meropenem, ciprofloxacin and amikacin respectively.Conclusion: Carbapenems have great bactericidal activity against Ps. aeruginosa, while, this notorious pathogen acquisition resistance against these drugs and limited treatment options. Our isolated strains showed a low rate of resistance (9%) and (5.8%) against imipenem and meropenem respectively. Aminoglycoside is crucial for the treatment of various Ps. aeruginosa infections. However, our study showed that (1.2%) of Ps. aeruginosa strains were resistances to amikacin and Ciprofloxacin has been extensively used to treat wide a variety of Ps. aeruginosa infections. While Ps. aeruginosa rapidly acquired resistance to ciprofloxacin that creating a therapeutic challenge. In this study, 10.38% of Ps. aeruginosa was found resistant to Ciprofloxacin. We recommended further studies and a regular monitoring system for the early detection of MBL-producing organisms.      

DOI

10.21608/eajbsg.2023.280058

Keywords

Pseudomonas aeruginosa, Metallo-β-lactamase, Intensive Care Units

Authors

First Name

Wafaa

Last Name

Abdulrahaman1

MiddleName

M. A.

Affiliation

Microbiology Dept. College of Medicine Batterjee Medical College. -Department of Medical Microbiology, College of Medical Laboratory Science, Kordofan University, Sudan.

Email

wafaaban@live.com

City

-

Orcid

-

First Name

Eldaw

Last Name

Mohamed

MiddleName

B. S.

Affiliation

Department of Medical Microbiology, College of Medical Laboratory Science, Kordofan University, Sudan.

Email

-

City

-

Orcid

-

First Name

Fatimah

Last Name

Saidi

MiddleName

M. S.

Affiliation

Physical therapy Dept. Batterjee Medical College

Email

-

City

-

Orcid

-

First Name

Mogahid

Last Name

Elhassan

MiddleName

M.

Affiliation

Nahrain College, Khartoum, Sudan. -Department of Medical Microbiology, College of Medical Laboratory Science, Sudan University of Science and Technology, Sudan

Email

-

City

-

Orcid

-

Volume

15

Article Issue

1

Related Issue

38907

Issue Date

2023-06-01

Receive Date

2022-10-29

Publish Date

2023-06-06

Page Start

1

Page End

11

Print ISSN

2090-0872

Online ISSN

2090-0880

Link

https://eajbsg.journals.ekb.eg/article_280058.html

Detail API

https://eajbsg.journals.ekb.eg/service?article_code=280058

Order

280,058

Type

Original Article

Type Code

689

Publication Type

Journal

Publication Title

Egyptian Academic Journal of Biological Sciences, G. Microbiology

Publication Link

https://eajbsg.journals.ekb.eg/

MainTitle

Frequency of Metallo-Β-Lactamase Among Pseudomonas aeruginosa Isolated from patients In Intensive Care Units and Operating Rooms

Details

Type

Article

Created At

22 Jan 2023